	US 11,753,455 B2
	Compounds for treatment of obesity
Nikolaj Kulahin Roed, Birkeroed (DK); Michael Paolo Bastner Sandrini, Alleroed (DK); Jesper Lau, Farum (DK); Paw Bloch, Jyllinge (DK); Anna Secher, Koebenhavn NV (DK); Adam Paul Chambers, Alleroed (DK); Jim McGuire, Berkeley, CA (US); and Lotte Bjerre Knudsen, Jerslev (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Appl. No. 17/253,708
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
PCT Filed Jun. 20, 2019, PCT No. PCT/EP2019/066358 § 371(c)(1), (2) Date Dec. 18, 2020, PCT Pub. No. WO2019/243502, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 18179022 (EP), filed on Jun. 21, 2018.
Prior Publication US 2021/0261641 A1, Aug. 26, 2021
Int. Cl. C07K 14/575 (2006.01); A61K 47/62 (2017.01); A61K 38/00 (2006.01)

CPC C07K 14/575 (2013.01) [A61K 47/62 (2017.08); A61K 38/00 (2013.01); C07K 2319/74 (2013.01)]

6 Claims

1. A construct comprising a GLP-1 analogue and means for binding allosterically to the transferrin receptor (TfR); or a pharmaceutically acceptable salt, amide, or ester thereof.